AlphAIAlphAI — Financial news for AI agents
investing.comSEP 152 min read$RMD

Why is ResMed stock rallying today?

ResMed (RMD) stock rose 2.9% after providing fiscal 2027 guidance, projecting 5%-7% revenue growth and 12%-14% EPS growth. RBC upgraded RMD to Outperform, raising its price target to $262. Despite broader market declines, RMD's positive outlook resonated with investors, addressing concerns about GLP-1 headwinds and competition.

Original reporting
investing.com
Published Sep 15, 2026, 7:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RMD
Bullish
high confidence
Mentioned
$RMD
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RMDBullishHigh
01

Why it matters

The guidance and upgrade provide a clear catalyst for short‑term buying, with upside potential if growth targets are met.

02

Market read

ResMed's stock rally contrasts with broader market declines, highlighting the impact of company‑specific guidance.

03

What to watch

Potential headwinds from the Astral field safety notice and macro‑rate environment.

Relevance 8/10Novelty 8/10Timing: afternoon trading today

Background

ResMed's guidance was presented at the Morgan Stanley Global Healthcare Conference amid a risk‑off market environment.

Company-level read

Ticker impact

$RMDBullishHigh confidence
Context

ResMed delivered its first formal fiscal 2027 guidance and received an analyst upgrade, driving a 2.9% price rise.

Expected impact

Potential upside of 5‑7% over the next 3‑6 months if guidance holds.

Evidence & confidence

Guidance numbers exceed prior expectations and the upgrade raises target price, indicating near‑term buying interest.

Market effects

Sector

Positive signal for the sleep‑apnea and broader medical device sector.

Regional

U.S. healthcare stocks may see modest gains.

Global

Limited to investors tracking US med‑tech equities.

Counterpoint

What could challenge this read

Guidance may be optimistic given upcoming GLP‑1 competition; price could be overstated.

Key entities

  • Company
    ResMed Inc.

    Medical device maker specializing in sleep‑apnea equipment.

  • Analyst
    RBC Capital Markets

    Upgraded ResMed to Outperform and raised price target.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 28
$RMDMed

Health Check: No 'Wharfie Time' curse as healthcare stocks kick away from the pack

ASX healthcare stocks, led by CSL (ASX:CSL) and ResMed (ASX:RMD), gained institutional investor interest, with Morgan Stanley noting increased overweight positions. RBC Capital upgraded several healthcare stocks, citing better-than-expected earnings. Healius (ASX:HLS) plans to sell Agilex for $160M to Novotech, addressing balance sheet challenges. Paradigm Biopharmaceuticals (ASX:PAR) delayed its trading resumption to address financial matters.

stockhead.com.au5 min
SEP 16
$RMDMed

CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded

RBC Capital Markets upgraded five ASX-listed healthcare stocks to outperform, citing positive earnings growth and attractive valuations. CSL (ASX: CSL) was highlighted for market share gains, with a $213 price target. ResMed (ASX: RMD) was noted for capital management, with a $262 target. Ramsay Healthcare (ASX: RHC) was praised for cost control, with a $68 target. Fisher & Paykel (ASX: FPH) showed strong growth, with a $52 target. Nanosonics (ASX: NAN) had mixed results but a $3.75 target.

fool.com.au2 min
SEP 16
$RMDMed

ResMed Shares Jump Following RBC Capital Upgrade to Outperform

ResMed (RMD) stock rose 3% after RBC Capital upgraded it to Outperform, raising the price target to $262. Analyst Craig Wong-Pan cited strong growth in sleep devices, both in the Americas and internationally, and projected high single-digit EPS growth over three years. The FDA's recall of a competing device also boosted sentiment.

tikr.com2 min
SEP 14
$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

yahoo.com3 min